Compugen company info

What does Compugen do?
Compugen (TLV:CGEN), (NASDAQ:CGEN) is a pioneering company in the realm of computational genomics, dedicated to deciphering the complexities of the human genome to develop novel therapeutics for immunotherapy. This company focuses on the discovery and development of first-in-class therapeutics for cancer and immune-related diseases, leveraging its proprietary computational discovery platform. In alignment with its scientific advancements, Compugen is actively engaged in multiple projects aimed at identifying and characterizing potential drug targets that are novel, with an overarching goal to bring innovation to treatment paradigms. As a single-market listed entity, Compugen aims to expand its pipeline of therapeutic candidates and foster collaborations that enhance its research and development capabilities, striving to achieve breakthroughs for unmet medical needs.
Compugen company media
Company Snapshot

Is Compugen a public or private company?

key
Ownership
Public

How many people does Compugen employ?

people
Employees
68

What sector is Compugen in?

pie chart
Sector
Health Care

Where is the head office for Compugen?

location pin
Head Office
Tel Aviv District, Israel

What year was Compugen founded?

founded flag
Year Founded
1993
What does Compugen specialise in?
/IT Solutions /Managed Services /Cloud Solutions /Data Management /Cyber Security /Device Lifecycle Management

What are the products and/or services of Compugen?

Overview of Compugen offerings
COM701, an immuno-oncology therapeutic antibody targeting PVRIG in clinical trials for various tumor types.
BAY 1905254, a therapeutic antibody for solid tumors in collaboration with Bayer targeting ILDR2.
CGEN-15001, a fusion protein for autoimmune diseases including multiple sclerosis and rheumatoid arthritis.
COM902, a therapeutic antibody designed to enhance T cell activity in cancer treatment by targeting TIGIT.

Who is in the executive team of Compugen?

Compugen leadership team
  • Dr. Anat  Cohen-Dayag Ph.D.
    Dr. Anat Cohen-Dayag Ph.D.
    CEO, President & Director
  • Dr. Zurit  Levine Ph.D.
    Dr. Zurit Levine Ph.D.
    Senior Vice President of Technology Innovation
  • Dr. Pierre  Ferre Ph.D.
    Dr. Pierre Ferre Ph.D.
    Vice President of Preclinical Development
  • Mr. Alberto  Sessa
    Mr. Alberto Sessa
    Chief Financial Officer
  • Dr. Eran  Ophir Ph.D.
    Dr. Eran Ophir Ph.D.
    Chief Scientific Officer
  • Ms. Yvonne  Naughton
    Ms. Yvonne Naughton
    Head of Investor Relations & Corporate Communications
  • Mr. Eran Ben Dor
    Mr. Eran Ben Dor
    General Counsel & Corporate Secretary
  • Ms. Dorit  Amitay
    Ms. Dorit Amitay
    Vice President of Human Resources